Literature DB >> 30151275

Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation.

Sofia Palacio1, Terri Pollack1, Rachel Silva-Smith1, Daniel A Sussman1, Peter J Hosein1.   

Abstract

Pancreatic cancer is projected to become the second leading cause of cancer death in the United States by 2030. Deleterious germline mutations can contribute to pancreatic cancer susceptibility. Herein we report a case of a patient with metastatic pancreatic adenocarcinoma to the lung and liver who was found to have a deleterious germline mutation in RAD51C who had a remarkable response to chemotherapy with FOLFIRINOX, a platinum-containing regimen.

Entities:  

Keywords:  Pancreatic adenocarcinoma; RAD51C; oxaliplatin

Year:  2018        PMID： 30151275      PMCID： PMC6087861          DOI： 10.21037/jgo.2018.03.11

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  11 in total

Review 1.  Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway.

Authors:  Hyungjin Kim; Alan D D'Andrea
Journal:  Genes Dev       Date:  2012-07-01       Impact factor: 11.361

2.  Germline RAD51C mutations in ovarian cancer susceptibility.

Authors:  F Coulet; A Fajac; C Colas; M Eyries; A Dion-Minière; R Rouzier; S Uzan; J-P Lefranc; M Carbonnel; F Cornelis; A Cortez; F Soubrier
Journal:  Clin Genet       Date:  2012-07-23       Impact factor: 4.438

3.  Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

Authors:  Kathryn P Pennington; Tom Walsh; Maria I Harrell; Ming K Lee; Christopher C Pennil; Mara H Rendi; Anne Thornton; Barbara M Norquist; Silvia Casadei; Alexander S Nord; Kathy J Agnew; Colin C Pritchard; Sheena Scroggins; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

4.  Bladder cancer: Mutations in DNA-damage-repair pathways confer platinum sensitivity.

Authors:  Peter Sidaway
Journal:  Nat Rev Urol       Date:  2017-02-14       Impact factor: 14.432

Review 5.  Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?

Authors:  Min Yuen Teo; Eileen M O'Reilly
Journal:  J Gastrointest Oncol       Date:  2016-10

6.  RAD51C--a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC).

Authors:  Kathrin Scheckenbach; Stephan E Baldus; Vera Balz; Marcel Freund; Petra Pakropa; Christoph Sproll; Karl-Ludwig Schäfer; Martin Wagenmann; Jörg Schipper; Helmut Hanenberg
Journal:  Oral Oncol       Date:  2013-12-06       Impact factor: 5.337

7.  Improved survival in women with BRCA-associated ovarian carcinoma.

Authors:  Ilana Cass; Rae Lynn Baldwin; Taz Varkey; Roxana Moslehi; Steven A Narod; Beth Y Karlan
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

8.  Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.

Authors:  Lars Jønson; Lise B Ahlborn; Ane Y Steffensen; Malene Djursby; Bent Ejlertsen; Susanne Timshel; Finn C Nielsen; Anne-Marie Gerdes; Thomas V O Hansen
Journal:  Breast Cancer Res Treat       Date:  2016-01-06       Impact factor: 4.872

9.  Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.

Authors:  Koji Shindo; Jun Yu; Masaya Suenaga; Shahriar Fesharakizadeh; Christy Cho; Anne Macgregor-Das; Abdulrehman Siddiqui; P Dane Witmer; Koji Tamura; Tae Jun Song; Jose Alejandro Navarro Almario; Aaron Brant; Michael Borges; Madeline Ford; Thomas Barkley; Jin He; Matthew J Weiss; Christopher L Wolfgang; Nicholas J Roberts; Ralph H Hruban; Alison P Klein; Michael Goggins
Journal:  J Clin Oncol       Date:  2017-08-02       Impact factor: 44.544

Review 10.  Interplay between Fanconi anemia and homologous recombination pathways in genome integrity.

Authors:  Johanna Michl; Jutta Zimmer; Madalena Tarsounas
Journal:  EMBO J       Date:  2016-04-01       Impact factor: 11.598
View more
  1 in total

1.  DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer.

Authors:  Sofia Palacio; Hannah S McMurry; Robert Ali; Talia Donenberg; Rachel Silva-Smith; Gina Wideroff; Daniel A Sussman; Caio M S Rocha Lima; Peter J Hosein
Journal:  J Gastrointest Oncol       Date:  2019-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.